Single nucleotide polymorphisms of HSP90AA1 gene influence response of SLE patients to glucocorticoids treatment

Yan-Feng Zou1, Jian-Hua Xu2, Yuan-Yuan Gu1, Fa-Ming Pan1, Jin-Hui Tao3, De-Guang Wang4, Sheng-Qian Xu2, Hui Xiao5, Pei-Ling Chen2, Shuang Liu2, Jing Cai2, Li Lian2, Sheng-Xiu Liu5, Chun-Wei Liang6, Guo Tian1, Qian-Ling Ye7, Hai-Feng Pan1, Hong Su1 and Dong-Qing Ye1

Abstract

Heat shock protein 90 (HSP90) is an important glucocorticoid receptor (GR) chaperone protein, and is supposed to be the key factor in regulating glucocorticoids (GCs) effects. The aim of the present study was to explore whether single nucleotide polymorphisms (SNPs) within HSP90AA1 gene affect the response of systemic lupus erythematosus (SLE) patients to GCs treatment. Two hundred and twenty-five SLE patients were treated with GCs (prednisone) for 12 weeks. SLE disease activity index (SLEDAI) was used to assess the response of SLE patients to GCs treatment, and patients were classified into sensitive group and insensitive group. HapMap database and Haploview software were used to select tag SNPs. Tag SNPs were genotyped by using multiplex SNaPshot method. Univariate and multivariate logistic regression analyses were used to discriminate the impact of SNPs of HSP90AA1 gene on the response of SLE patients to GCs treatment. Two hundred and thirty-three SLE patients finished the 12-week follow-up. Of these patients, 128 patients were included in sensitive group, and 105 patients were included in insensitive group. Seven tag SNPs were selected within HSP90AA1 gene. We detected significant associations for rs7160651 (dominant model: crude OR 0.514, 95 % CI 0.297–0.890, \( P = 0.018 \); adjusted OR 0.518, 95 % CI 0.293–0.916, \( P = 0.024 \)), rs10873531 (dominant model: crude OR 0.516, 95 % CI 0.305–0.876, \( P = 0.014 \); adjusted OR 0.522, 95 % CI 0.304–0.898, \( P = 0.019 \)) and rs2298877 (dominant model: crude OR 0.543, 95 % CI 0.317–0.928, \( P = 0.026 \); adjusted OR 0.558, 95 % CI 0.323–0.967, \( P = 0.037 \)) polymorphisms, but not for other polymorphisms (\( P > 0.05 \)). The present study demonstrates that HSP90AA1 gene SNPs may affect the response of SLE patients to GCs treatment.

Keywords: Systemic lupus erythematosus, Glucocorticoids, Heat shock protein 90, Single nucleotide polymorphisms

Background

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by multiorgan dysfunction including neural, cardiovascular, pulmonary, renal, musculoskeletal and cutaneous systems (Rahman and Isenberg 2008; Chalayer et al. 2014). The etiology of SLE is partially known, and multiple genetic and environmental factors are involved (Moser et al. 2009). The ascertainment of SLE prevalence and incidence faces difficulty, and the results of studies on prevalence (range from 20 to 70 per 100,000 persons) and incidence (range from 1 to 10 per 100,000 person-years) of SLE in the general population show marked differences (Borchers et al. 2010; Pons-Estel et al. 2010). The number of patients with SLE exceeds 250,000 in the United States (Rahman and Isenberg 2008). In the past few decades, the life expectancy of SLE patients has improved from an approximate 4-year survival rate of 50 % to a 15-year survival rate of 80 % (Rahman and Isenberg 2008; Merrell and Shulman 1955; Abu-Shakra et al. 1995). However, SLE patients often suffer long-term morbidity that can adversely affect their ability to work as well as quality of life (Pons-Estel et al. 2010).
2010). The direct and indirect costs of SLE are substantial among working-age adults, especially in female.

Glucocorticoids (GCs) are currently the mainstay of SLE therapy. Generally, the majority of patients with SLE respond favorably to GCs. However, a lot of evidence of wide interindividual differences in GC efficacy and toxicity among patients have been observed (van Rossum and van den Akker 2011; De Ludicibus et al. 2011). The mechanisms by which interindividual differences develop are not yet fully understood. Genetic factors could, in part, explain the interindividual differences (Cronstein 2006). The effects of GCs are mediated through glucocorticoid receptor (GR), which, a transcription factor, binds steroid hormone ligands to affect the transcription of a number of target genes (Ito et al. 2006; Adcock et al. 1999). The transcriptional activity of GR is regulated by every step of its activation, including ligand binding, transcriptional cofactor binding, nuclear translocation, and DNA binding (Charmandari et al. 2008; Silverman and Sternberg 2008; Ouyang et al. 2012). Heat shock protein 90 (HSP90) is an important GR-related chaperone protein. It is supposed to be the key factor in regulating GCs effects and is essential for activated GR translocation as well as transactivation (Grad and Picard 2007; Murphy 2005).

The HSP90AA1 gene is located on the long arm in human chromosome 14 and a number of single nucleotide polymorphisms (SNPs) of GR gene have been described (Chen et al. 2005). Our previous study has showed that GR genetic variations may play a major role in the response of SLE patients to GCs treatment (Zou et al. 2013b). However, to our knowledge, these is no study to explore the association between HSP90AA1 genetic polymorphisms and the response to GCs in patients with SLE. Therefore, in this study, we enrolled 245 SLE patients treated with GCs (prednisone), and assessed the response of SLE patients to GCs treatment. HSP90AA1 gene SNPs were genotyped by using multiplex SNaPshot method. We explored whether SNPs within HSP90AA1 gene are related to the response of Chinese SLE patients to GCs treatment.

Results and discussion
Baseline characteristics of patients, genotype frequencies and results of Hardy–Weinberg equilibrium
Two hundred and thirty-three patients (95.10 %) completed the 12-week follow-up. Of these patients, 128 were classified as GCs-sensitive, while 105 patients were classified as GCs-insensitive, including twenty patients used other immunosuppressive agents because of lack of efficacy. No significant difference was found in sex (male: 7.03 vs 6.67 %), age (32.69 ± 11.27 vs 34.16 ± 11.09), body mass index (BMI) (20.76 ± 2.74 vs 21.17 ± 3.50), marital status (married: 72.66 vs 76.19 %), smoking (4.69 vs 1.90 %), alcohol drinking (10.94 vs 14.29 %), baseline SLE disease activity index (SLEDAI) score (11.92 ± 1.91 vs 11.50 ± 2.69) and GCs dose (45.55 ± 14.90 vs 42.57 ± 17.06) between GCs-sensitive group and GCs-insensitive group (Table 1, P > 0.05). The genotype frequencies of HSP90AA1 gene 7 tag SNPs were evaluated and were reported in Table 2. The genotype distributions of these SNPs were in Hardy–Weinberg equilibrium (P > 0.05). Twelve patients failed to attend scheduled clinic visits. The clinical and demographic characteristics of the dropouts did not differ significantly from the completers (P > 0.05).

Association of HSP90AA1 gene polymorphisms with response of SLE patients to GCs
Univariate logistic analysis showed that the following three HSP90AA1 gene tag SNPs were significantly associated with the response of SLE patients to GCs treatment: rs7160651 (dominant model: OR 0.514, 95 % CI 0.304–0.898, P = 0.018), rs10873531 (dominant model: OR 0.516, 95 % CI 0.305–0.876, P = 0.014) and rs2298877 (dominant model: OR 0.518, 95 % CI 0.293–0.916, P = 0.024; rs10873531 dominant model: OR 0.522, 95 % CI 0.304–0.898, P = 0.019; rs2298877 dominant model: OR 0.558, 95 % CI 0.323–0.967, P = 0.037). The results of univariate and multivariate logistic regression analyses are shown in Table 3.

In the present study, we evaluated the effects of SNPs within HSP90AA1 gene on the efficacy of GCs treatment for SLE patients. We observed significant associations of HSP90AA1 gene rs7160651, rs10873531 and rs2298877 polymorphisms with GCs efficacy in Chinese patients with SLE. Our results demonstrate that HSP90AA1 gene polymorphisms may play a role in the response of SLE patients to GCs treatment.

GCs have well-known immunosuppressive effects and are one of the most widely used anti-inflammatory agents in SLE treatment. Despite the proven effectiveness and extensive use, interindividual differences in the response of SLE patients to GCs treatment have been reported, and some patients do not achieve complete remission, or else improve very slowly (van Rossum and van den Akker 2011; De Ludicibus et al. 2011). Meanwhile, the potential for many serious adverse events, including metabolic disease, osteoporosis and increased risk of cardiovascular disease mar the clinical use of GCs (Saag 2002; de Vries et al. 2007; Wang et al. 2012). Patients, especially for those who respond poorly to GCs, are at high risk of adverse events. GCs cause their effects by binding to
GR, which is localized in the cytoplasm of target cells, and after binding the ligand, GR-ligand complexes are constructed and translocated into the nucleus (Ito et al. 2006; Adcock et al. 1999). The function of GR is crucially dependent on interactions with HSP90 which facilitates GCs binding to the GR (Grad and Picard 2007; Murphy 2005).

Similarities in the pathologies of cancer and autoimmune diseases, including SLE, have been noted for many years (Eck et al. 2009). HSP90 has been widely studied in cancer. New evidence continues to suggest that HSP90 is overexpressed and associated with poor prognosis in many cancers. Wang et al. (2013) estimated the association of HSP90 expression with clinicopathological parameters, prognosis and the alteration of HSP90 expression after neoadjuvant chemotherapy in patients with advanced gastric cancer. The results showed that HSP90 expression was significantly associated with tumor site, tumor size, depth invasion, lymph node metastasis as well as clinical stages, and the patients with HSP90-positive had worse prognosis than those patients with HSP90-negative. Their study suggested that HSP90 plays an important role on tumor prognosis and may act as a promising target for prognostic prediction in gastric cancer. Tanaka et al. (2013) characterized the efficacy of a potent HSP90 inhibitor NXD30001 against neurofibromatosis type 2 (NF2)-related tumors in vitro and in vivo. Their study showed that HSP90 inhibition has significant antitumor activity against NF2-related tumor cells in vitro and in vivo, and provided certain evidence for the benefit of the HSP90 inhibition against NF2-related tumors. Chu et al. (2013) estimated the role of HSP90AA1 in ovarian cancer and their study suggested that HSP90AA1 is required for the proliferation and survival of SKOV3 cells. They found

| Characteristic | Sensitive (n = 128) | Insensitive (n = 105) | Overall (n = 233) | P value |
|----------------|---------------------|----------------------|-------------------|---------|
| Sex, No. (%)   |                     |                      |                   | 0.913   |
| Male           | 9 (7.03)            | 7 (6.67)             | 16 (6.87)         |         |
| Female         | 119 (92.97)         | 98 (93.33)           | 217 (93.13)       |         |
| Age, mean (SD) | 32.69 (11.27)       | 34.16 (11.09)        | 33.35 (11.19)     | 0.318   |
| BMI, mean (SD) | 20.76 (2.74)        | 21.17 (3.50)         | 20.95 (3.10)      | 0.333   |
| Marital status, No. (%) |       |                      |                   | 0.539   |
| Unmarried      | 35 (27.34)          | 25 (23.81)           | 60 (27.75)        |         |
| Married        | 93 (72.66)          | 80 (76.19)           | 173 (74.25)       |         |
| Smoking, No. (%) |                   |                      |                   | 0.246   |
| No             | 122 (95.31)         | 103 (98.10)          | 225 (96.57)       |         |
| Yes            | 6 (4.69)            | 2 (1.90)             | 8 (3.43)          |         |
| Drinking, No. (%) |                 |                      |                   | 0.441   |
| No             | 114 (89.06)         | 90 (85.71)           | 204 (87.55)       |         |
| Yes            | 14 (10.94)          | 15 (14.29)           | 29 (12.45)        |         |
| SLEDAI, mean (SD) |                |                      |                   | 0.174   |
| No             | 11.92 (1.91)        | 11.50 (2.69)         | 11.73 (2.30)      |         |
| Yes            | 22.61 (2.91)        | 23.05 (3.67)         | 22.83 (3.34)      |         |
| GCs dose mg/d, mean (SD) |         |                      |                   | 0.157   |
| No             | 45.55 (14.90)       | 42.57 (17.06)        | 44.21 (15.94)     |         |
| Yes            | 56.68 (10.24)       | 53.02 (14.17)        | 54.85 (12.57)     |         |

| Polymorphisms (Minor allele) | Sensitive (n = 128) | Insensitive (n = 105) | Overall (n = 233) | HWE P value |
|-----------------------------|---------------------|----------------------|-------------------|-------------|
| Wild type                   | 121 (94.53)         | 97 (92.38)           | 218 (93.56)       | 0.612       |
| rs2298878 (A)               | 7 (5.47)            | 8 (7.62)             | 15 (6.44)         |             |
| Heterozygous                | 0 (0)               | 0 (0)                | 0 (0)             |             |
| Homozygous mutants          |                     |                      |                   |             |
| rs7157967 (C)               | 123 (96.09)         | 103 (98.10)          | 226 (97.00)       | 0.816       |
| Wild type                   | 5 (3.91)            | 2 (1.90)             | 7 (3.00)          |             |
| Heterozygous                | 0 (0)               | 0 (0)                | 0 (0)             |             |
| Homozygous mutants          |                     |                      |                   |             |
| rs7160651 (A)               | 72 (56.25)          | 75 (71.43)           | 147 (63.09)       | 0.964       |
| Wild type                   | 50 (39.06)          | 26 (24.76)           | 76 (32.62)        |             |
| Heterozygous                | 6 (4.69)            | 4 (3.81)             | 10 (4.29)         |             |
| Homozygous mutants          | 9 (7.03)            | 11 (9.47)            | 15 (6.43)         |             |
| rs10873531 (G)              | 61 (47.66)          | 67 (63.81)           | 128 (54.94)       | 0.877       |
| Wild type                   | 59 (46.09)          | 31 (29.52)           | 90 (38.63)        |             |
| Heterozygous                | 8 (6.25)            | 7 (6.67)             | 15 (6.43)         |             |
| Homozygous mutants          | 6 (4.75)            | 1 (0.95)             | 3 (1.29)          |             |
| rs1190597 (G)               | 107 (83.59)         | 94 (89.53)           | 201 (86.26)       | 0.112       |
| Wild type                   | 19 (14.85)          | 10 (9.52)            | 29 (12.45)        |             |
| Heterozygous                | 2 (1.56)            | 1 (0.95)             | 3 (1.29)          |             |
| Homozygous mutants          | 94 (75.36)          | 11 (10.48)           | 15 (6.43)         |             |
| rs11547523 (G)              | 111 (86.72)         | 94 (89.52)           | 205 (87.98)       | 0.913       |
| Wild type                   | 16 (12.50)          | 11 (10.48)           | 27 (11.59)        |             |
| Heterozygous                | 1 (0.78)            | 0 (0)                | 1 (0.43)          |             |
| Homozygous mutants          | 94 (75.36)          | 11 (10.48)           | 15 (6.43)         |             |
| rs2298877 (T)               | 68 (53.13)          | 71 (67.62)           | 139 (59.66)       | 0.585       |
| Wild type                   | 53 (41.41)          | 27 (23.71)           | 80 (34.33)        |             |
| Heterozygous                | 7 (5.46)            | 7 (6.67)             | 14 (6.01)         |             |
| Homozygous mutants          | 71 (56.87)          | 27 (23.71)           | 80 (34.33)        |             |
Table 3  Analysis of glucocorticoids efficacy and single nucleotide polymorphisms of HSP90AA1 gene

| Polymorphisms | Dominant model | Recessive model |
|---------------|----------------|-----------------|
|               | Crude OR (95 % CI) | Crude P value | Adjusted OR (95 % CI) | Adjusted P value | Crude OR (95 % CI) | Crude P value | Adjusted OR (95 % CI) | Adjusted P value |
| rs2298878     | 1.426 (0.499–4.070) | 0.508 | 1.508 (0.516–4.405) | 0.453 | – | – | – | – |
| rs7157967     | 0.478 (0.091–2.515) | 0.384 | 0.380 (0.065–2.212) | 0.282 | – | – | – | – |
| rs7160651     | 0.514 (0.297–0.890) | 0.018 | 0.518 (0.293–0.916) | 0.024 | 0.805 (0.221–3.072) | 0.743 | 0.946 (0.251–3.640) | 0.935 |
| rs10873531    | 0.516 (0.305–0.876) | 0.014 | 0.522 (0.304–0.898) | 0.019 | 1.072 (0.375–3.059) | 0.897 | 1.259 (0.425–3.729) | 0.678 |
| rs1190597     | 0.596 (0.273–1.301) | 0.014 | 0.562 (0.251–1.259) | 0.012 | 0.606 (0.054–6.775) | 0.684 | 0.473 (0.040–5.611) | 0.553 |
| rs11547523    | 0.764 (0.341–1.712) | 0.013 | 0.795 (0.349–1.813) | 0.056 | – | – | – | – |
| rs2298877     | 0.543 (0.317–0.928) | 0.026 | 0.558 (0.323–0.967) | 0.037 | 1.235 (0.419–3.639) | 0.702 | 1.429 (0.466–4.380) | 0.532 |
that HSP90AA1 RNAi could inhibit the proliferation and increase the apoptosis of ovarian cancer SKOV3 cell line. They also found that high expression of HSP90AA1 could partially rescue the survival rate of SKOV3 cells which were treated with cisplatin and decrease the chemosensitivity to cisplatin of SKOV3 cells. Recently, Coskunpinar et al. (2014) investigated HSP90AA1 gene polymorphisms in patients with non-small cell lung cancer (NSCLC). They found that the frequency of mutant genotypes for HSP90AA1 gene rs4947 polymorphism was significantly higher in the patient group than the frequency in controls, indicating that HSP90AA1 gene polymorphisms may contribute to NSCLC development. In SLE patients, high expression of HSP90 has also been detected and correlated with increased levels of IL-6 as well as presence of autoantibodies to HSP90, suggesting that targeting HSP90 may be an effective treatment for SLE (Shukla and Pitha 2012; Hu et al. 2006). In MRL/lpr mouse model of SLE, Shimp et al. (2012) estimated if HSP90 inhibition would reduce disease, and their results suggested that HSP90 may play a role in regulating T cell differentiation as well as activation and that inhibition of HSP90 may reduce inflammation in SLE. Moreover, a recent study has suggested that the accumulation of HSP90 in the nucleus potentially hinders DNA-binding activity and transactivation, which may contribute to GCs resistance in patients with idiopathic nephrotic syndrome (INS) (Ouyang et al. 2012). The above evidence appears to support our results. Since HSP90 protein expression may have an impact on cellular sensitivity to systemic GCs treatment, SNPs within HSP90AA1 gene may contribute to decreased/increased GCs responsiveness. However, these is no other study to explore the association of HSP90AA1 gene polymorphisms with the response of SLE patients to GCs treatment. Further studies are still needed to assess the current results. The association may result from the direct effect of these polymorphisms themselves, or through linkage disequilibrium with another functional polymorphisms in the structural or regulatory regions of the gene. Further studies of the function of these polymorphisms are needed.

The sample size of the current study is limited. Twelve patients dropped out of the study. Additionally, the use of hydroxychloroquine, considered as a second-line treatment in SLE patients, offers a wide range of benefits (Costedoat-Chalumeau et al. 2010; Chen et al. 2015). Thus, patients also received hydroxychloroquine therapy in the study. These limitations may have certain impact on our results.

**Conclusion**

In conclusion, this is the first study to explore the association of the response to GCs with HSP90AA1 genetic polymorphisms in SLE patients. The present study demonstrates that HSP90AA1 gene rs7160651, rs10873531 and rs2298877 polymorphisms may affect the response of SLE patients to GCs treatment. Larger studies are required to further assess the association. Meanwhile, further studies of the function of these polymorphisms are needed.

**Methods**

**Subjects and study design**

In order to interpret genetic and environmental influence on individualized response to treatment in SLE patients, a pharmacogenetic study was conducted in Anhui Medical University. This study was carried out as part of the pharmacogenetic study. A total of 245 patients, enrolled in the First Affiliated Hospital and the Second Affiliated Hospital of Anhui Medical University (Anhui, China), were included in the study. All patients were of unrelated Han Chinese ancestry, and met the revised criteria for the classification of SLE established by the American College of Rheumatology (ACR) in 1997 (Hochberg 1997). These patients have the SLEDAI score of 5 or higher, and no patients had recent exposure to GCs (in the last three months). Potential patients were excluded if they: (1) had lupus crisis or required GCs plus therapy; (2) had systemic fungal or bacterial infection; (3) were pregnant or lactating women; (4) were allergic to hydroxychloroquine. The treatment and efficacy assessment used for the present study has been described in our previous study (Zou et al. 2013a, b). Briefly, patients were treated with GCs (prednison) combined with hydroxychloroquine (400 mg/day) for 12 weeks. At the start of the study, prednisonone 10 mg/day–0.5 mg/kg/day was administrated to the patients whose SLEDAI scores were <10, and 0.5–1 mg/kg/day was administrated to the patients whose SLEDAI scores were ≥10. The dosage adjustments were made through the consultation from the rheumatologists during the course of treatment. SLEDAI was used to assess the response of SLE patients to GCs treatment at weeks 0, 4, 8 and 12. The GCs-sensitive was defined as a 4 points or less in the SLEDAI score at the 12 weeks. The GCs-insensitive was defined as a 5 points or greater in the SLEDAI score at the 12 weeks, and patients who took other immunosuppressive agents because of lack of efficacy in the course of treatment were also considered as GCs-insensitive. The ethical committee of Anhui Medical University approved the study. We obtained written informed consent from all patients and fully explained the procedures of the study.

**Tag SNP selection and genotyping**

HapMap database and Haploview software were used to select tag SNPs. SNPs within HSP90AA1 gene were...
Statistical analysis
Mean and standard deviation (SD) of continuous variables, and proportions of categorical variables are presented as descriptive statistics. Differences for continuous variables were tested by using t-test. Chi square test was used to test differences for categorical variables and Hardy–Weinberg equilibrium. Dominant and recessive models were applied for the analysis of genotype distribution. Univariate and multivariate logistic regression analyses were used to discriminate the impact of SNPs of HSP90AA1 gene on the response of SLE patients to GCs treatment (GCs-sensitive 0, GCs-insensitive 1). We used multivariate logistic regression to adjust for potential confounding factors (sex, age, BMI, marital status, smoking status, alcohol drinking, baseline SLEDAI score and GCs dose (mg/day)). All statistical analyses were performed using SPSS software version 10.01 (SPSS, Inc, Chicago, IL). Within this report, P < 0.05 were considered statistically significant.

Abbreviations
SLE: systemic lupus erythematosus; GCs: glucocorticoids; GR: glucocorticoid receptor; HSP90: heat shock protein 90; SNPs: single nucleotide polymorphisms; BMI: body mass index; SLEDAI: SLE disease activity index; NF2: neurofibromatosis type 2; NSCLC: non-small cell lung cancer; INS: idiopathic nephrotic syndrome; ACR: American College of Rheumatology; MAF: minor allele frequency; SD: standard deviation.

References
Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. II Predator variables for mortality. J Rheumatol 22:1265–1270
Adcock IM, Naisbith J, Stevens DA, Barnes PJ (1999) Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation preferential targeting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol 127:1003–1011
Borchers AT, Naguva SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:A277–A287
Chalayer E, Fiorench M, Cathebras P (2014) one marrow fibrosis as a feature of systemic lupus erythematosus: a case report and literature review. Springerplus 3.349. doi.org/10:1186/2193-1801-3-349
Charmandari E, Kino T, Ichijo T, Chrousos GP (2008) Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms, and implications of a rare genetic disorder. J Clin Endocrinol Metab 93:1563–1572
Chen B, Piel WH, Gui L, Bruford E, Monteiro A (2005) The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 86:627–637
Chen YM, Lin CH, Lan TH, Chen HH, Chang SN, Chen YH, Wang JS, Hung WT, Lan JL, Chen Y (2015) Hydroxychloroquine reduces risk of incident diabetes mellitus in lupus patients in a dose-dependent manner: a population-based cohort study. Rheumatology 54:1244–1249
Chu SH, Liu YW, Zhang L, Li B, Li L, Shi JZ, Li L (2013) Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells. Mol Biol Rep 40:1–6
Coskunpinar E, Akkaya N, Yildiz P, Ozturk YM, Aynaci E, Isbir T, Yalim I (2014) The significance of HSP90AA1, HSP90AB1 and HSP90B1 gene polymorphisms in a Turkish population with non-small cell lung cancer. Anticancer Res 34:753–757
Costedoat-Chalumeau N, Leroux G, Pette JC, Amoura Z (2010) Why all systemic lupus erythematosus patients should be given hydroxychloroquine treatment? Joint Bone Spine 77:4–5
Cronstein BN (2006) Pharmacogenetics in the rheumatic diseases. Bull NYU Hosp Jt Dis 64:16–19
De Iudicibus S, Franca R, Tartoloski S, Ventura A, Decorti G (2011) Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease. World J Gastroenterol 17:1095–1108
de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, van Staaij TP (2007) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 261:170–177
Eck SM, Blackburn JS, Schmucker AC, Burrous PS, Brinkerhoff CE (2009) Matrix metalloproteinase and G protein coupled receptors: co-conspirators in the pathogenesis of autoimmune disease and cancer. J Autoimmun 33:214–221
Grad I, Picard D (2007) The glucocorticoid responses are shaped by molecular chaperones. Mol Cell Endocrinol 275:2–12
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
Hu S, Xu Q, Xiao W, Huang M (2006) The expression of molecular chaperone HSP90 and IL-6 in patients with systemic lupus erythematosus. J Huazhong Univ Sci Technol Med Sci 26:664–666
Ito K, Chung KF, Adcock IM (2006) Update on glucocorticoid action and resistance. J Allergy Clin Immunol 117:522–543
Merrell M, Shulman LE (1955) Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1:12–32
Moser KL, Kelly JA, Lessard CJ, Harley JB, Moser KL, Kelly JA, Harley JB, Lessard CJ (2009) Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 10:373–379
Murphy PJ (2005) Regulation of glucocorticoid receptor steroid binding and trafficking by the hsp90/hsp70-based chaperone machinery: implications for clinical intervention. Leukemia 19:710–712
Ouyang J, Chen P, Jiang T, Chen Y, Lu J (2012) Nuclear HSP90 regulates the glucocorticoid responsiveness of PBMCs in patients with idiopathic nephritic syndrome. Int Immunopharmacol 14:334–340
Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39:267–280
Rahman A, Isenberg DA (2008) Systemic lupus erythematosus. N Engl J Med 358:929–939
Saag KG (2002) Glucocorticoid use in rheumatoid arthritis. Curr Rheumatol Rep 4:218–225
Shimp SK 3rd, Chaffin CB, Regna NL, Hammond SE, Read MA, Caudell DL, Rylander M, Reilly CM (2012) Heat shock protein 90 inhibition by 17-DAMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cell Mol Immunol 9:255–266
Shukla HD, Pitha PM (2012) Role of hsp90 in systemic lupus erythematosus and its clinical relevance. Autoimmune Dis 2012:728605. doi:10.1155/2012/728605
Silverman MN, Sternberg EM (2008) Neuroendocrine-immune interactions in rheumatoid arthritis: mechanisms of glucocorticoid resistance. NeuroImmunoModulation 15:19–28
Tanaka K, Eskim A, Chareyre F, Jessen WJ, Manent J, Niwa-Kawakita M, Chen R, White CH, Vitte J, Jaffer ZM, Nelson SF, Rubenstein AE, Giovannini M (2013) Therapeutic potential of HSP90 inhibition for neurofibromatosis type 2. Clin Cancer Res 19:3856–3870
van Rossum EF, van den Akker EL (2011) Glucocorticoid resistance. Endocr Dev 20:127–136
Wang XY, Tang XQ, Huang YJ, Chen WY, Yu XQ (2012) Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus. Clin Rheumatol 31:669–675
Wang J, Cui S, Zhang X, Wu Y, Tang H (2013) High expression of heat shock protein 90 is associated with tumor aggressiveness and poor prognosis in patients with advanced gastric cancer. PLoS One 8:e62876. doi:10.1371/journal.pone.0062876
Zou YF, Xu JH, Tao JH, Xu SQ, Liu S, Chen SY, Cai J, Liu L, Chen PL, Wang DG, Liu SX, Liang CY, Ye QT, Tian G, Wu M, Pan HF, Pan FM, Su H, Ye DQ (2013a) Impact of environmental factors on efficacy of glucocorticoids in Chinese population with systemic lupus erythematosus. Inflammation 36:1424–1430
Zou YF, Xu JH, Wang F, Liu S, Tao JH, Cai J, Liu L, Xiao H, Chen PL, Tian G, Wu M, Wang DG, Liu SX, Liang CY, Pan FM, Su H, Pan HF, Ye DQ (2013b) Association study of glucocorticoid receptor genetic polymorphisms with efficacy of glucocorticoids in systemic lupus erythematosus: a prospective cohort study. Autoimmunity 46:531–536